Dependence of mesolimbic dopamine transmission on delta9-tetrahydrocannabinol

Eur J Pharmacol. 1999 Jul 2;376(1-2):23-6. doi: 10.1016/s0014-2999(99)00384-2.

Abstract

Rats were administered daily for 8 days with increasing doses (2-12 mg/kg/day) of delta9-tetrahydrocannabinol (delta9-THC) and than challenged with different doses of SR141716A, an antagonist of cannabinoid receptors. SR141716A dose dependently reduced dialysate dopamine (DA) in the nucleus accumbens shell and precipitated a physical withdrawal syndrome. No such effects were obtained after administration of SR141716A to saline controls.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Behavior, Animal / drug effects
  • Cannabinoids / antagonists & inhibitors
  • Dopamine / metabolism
  • Dopamine / physiology*
  • Dronabinol / pharmacology*
  • Dronabinol / toxicity
  • Hallucinogens / pharmacology*
  • Hallucinogens / toxicity
  • Male
  • Microdialysis
  • Nucleus Accumbens / drug effects*
  • Nucleus Accumbens / physiology
  • Piperidines / pharmacology
  • Pyrazoles / pharmacology
  • Rats
  • Rats, Sprague-Dawley
  • Receptors, Cannabinoid
  • Receptors, Drug / antagonists & inhibitors
  • Rimonabant
  • Substance Withdrawal Syndrome / physiopathology
  • Substance-Related Disorders / physiopathology*

Substances

  • Cannabinoids
  • Hallucinogens
  • Piperidines
  • Pyrazoles
  • Receptors, Cannabinoid
  • Receptors, Drug
  • Dronabinol
  • Rimonabant
  • Dopamine